| Name | Title | Contact Details |
|---|
BASi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. We provide world-class research to the global pharmaceutical industry. Our services include Preclinical Toxicology, Early In Vivo PK, Bioanalysis and a full range of pharmaceutical analysis services. BASi also manufactures innovative scientific instruments including the Culex® Automated In Vivo Sampling System which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. We are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
As part of the state`s premier academic medical center, University of Missouri Health Care offers a full spectrum of care, ranging from primary care to highly specialized, multidisciplinary treatment for patients with the most severe illnesses and injuries. Patients from each of Missouri`s 114 counties are served by approximately 6,000 physicians, nurses and health care professionals at MU Health Care. MU Health Care is a part of University of Missouri Health System, which also includes the MU School of Health Professions, the MU School of Medicine, the MU Sinclair School of Nursing and University Physicians practice plan. University Hospital includes: The Frank L. Mitchell Jr., MD Trauma Center. A nationally accredited Cycle II Chest Pain Center and a nationally accredited Primary Stroke Center, the George D. Peak Memorial Burn and Wound Center. University of Missouri Women`s and Children`s Hospital is Missouri`s only hospital dedicated to women and children. It is the largest pediatric health care facility in mid-Missouri. Ellis Fischel Cancer Center is Missouri`s only hospital dedicated solely to cancer care. Missouri Orthopaedic Institute is the newest and largest freestanding orthopaedic center in mid-Missouri. The Missouri Psychiatric Center offers short-term, intensive inpatient treatment services for adults, adolescents and children at our facility adjacent to University Hospital.
Aldera is the new name for Healthation. Healthation accelerated the business of healthcare. Aldera brings the focus and foresight to improve it. While our name has changed, our solutions remain resilient. Our service remains deeply rooted in customer commitment. The post-healthcare reform landscape is a frontier fraught with challenges. Our expert knowledge of the terrain and our flexible payer platform prepares healthcare payers and administrators to confidently navigate the shifts.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.